Complex Generics & 505(b)(2) Pathway Planner

Planning aid, not a regulatory determination. This tool applies general FDA pathway logic (21 CFR 314 Subpart C for ANDAs; 21 CFR 314.54 for 505(b)(2) applications relying in part on the Agency's finding of safety/effectiveness for a different but related product) to help teams reason about likely pathway and typical bioequivalence evidence expectations for a dosage-form class. It does not review your specific product, does not query FDA's product-specific guidance (PSG) database, and cannot substitute for a qualified regulatory affairs professional confirming the actual pathway and BE requirements for your drug with FDA (including a pre-submission meeting where warranted).

Product Characterization

Route of Administration

Release Mechanism

Relationship to a Previously Approved Product

Same active, same dosage form, same route, same strength as an approved RLD You intend to match a Reference Listed Drug exactly (the classic generic-copy scenario). Different dosage form and/or route from an approved product of the same active e.g., approved oral tablet exists, you are developing a long-acting injectable of the same molecule. New combination or new indication built on a previously approved active e.g., a fixed-dose combination or new indication using an active with an existing approval. Genuinely novel active (no prior US approval to rely on) New molecular entity — out of scope for this generics/505(b)(2) tool.

Pathway Determination

Complete the product characterization and click "Classify Pathway" to view the decision-support output.

Typical Bioequivalence Method Pattern for This Dosage-Form Class

These are general, class-level patterns drawn from how FDA has historically approached bioequivalence for these dosage forms. Actual requirements are product-specific guidance (PSG)-driven and can differ by drug, strength, and indication. Always confirm against the current FDA product-specific guidance for your exact drug substance and dosage form before finalizing a BE strategy.

Evidence Gap Checklist

Why Complex Generics Cost More & Take Longer - And Where Planning Automation Helps

Dimension	Oral-Solid ANDA (typical)	Complex Generic / 505(b)(2) (typical)
BE method	Dissolution (f2) often sufficient; in vivo PK BE common but well-established	Often requires specialized in vitro characterization (e.g. IVRT/IVPT, particle size/morphology) plus in vivo PK, sometimes clinical endpoint studies
Formulation matching	Q1/Q2 (qualitative/quantitative sameness) usually sufficient	Often needs Q1/Q2/Q3 (including physicochemical/structural sameness) for topicals and complex formulations
Analytical method maturity	Standardized, widely precedented	Frequently requires bespoke method development/validation (e.g., IVRT, permeation, particle-size methods)
FDA review cycles	Typically fewer deficiency cycles for well-precedented forms	Historically more review cycles / complete response letters due to novel evidence packages
Clinical/PK study likelihood	Low-to-moderate	Moderate-to-high, especially for depot injectables, OINDP, and some ophthalmic suspensions
Typical development timeline	Shorter, more predictable	Longer, less predictable — directional only, not a guaranteed multiplier

This comparison is directional and illustrative — it is not a fabricated numeric cost/timeline multiplier. Actual cost and timeline depend on the specific drug, dosage form, PSG maturity, and FDA's current thinking for that product class.

Where planning automation genuinely helps: in silico permeation/release modeling to narrow candidate formulations before committing to expensive in vitro/in vivo studies, automated extraction of PSG requirements so teams don't miss a required test method, and evidence-gap analysis that flags likely deficiency risk before submission. Automation here is a planning accelerant that helps identify the right testing strategy earlier - it does not replace the actual required in vitro, in vivo, or clinical studies, and it does not predict FDA approval outcomes.